Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | GRN | P28799 | 1/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521678 | 0.88 | DRD4 (0.57) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| SCHEMBL3519935 | 0.88 | DRD4 (0.57) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| SCHEMBL27641050 | 0.88 | DRD4 (0.57) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| SCHEMBL159384 | 0.88 | DRD4 (0.57) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| SCHEMBL28957814 | 0.88 | DRD4 (0.57) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| SCHEMBL12696566 | 0.87 | DRD4 (0.56) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| Hydrochloric Acid SCHEMBL12610644 | 0.87 | DRD4 (0.56) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| SCHEMBL4129378 | 0.87 | DRD4 (0.56) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| Hydrochloric Acid SCHEMBL12610726 | 0.87 | DRD4 (0.56) | DRD4GRIN2BDRD2DRD3CYP1A2 | |
| SCHEMBL4836218 | 0.87 | DRD4 (0.56) | DRD4GRIN2BDRD2DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130339-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| EP-2867236-B1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2867236-A1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | Pfizer Inc. (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014001973-A1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | PFIZER (US) | 2014-01-02 | — | — | US | disclosed |
| WO-2011058478-A1 | SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058478-A1 | SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1729754-B1 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130339-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | DRD4 3690/4885GRIN2B 401/4885DRD2 3167/4885 |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | DRD4 57/4885GRIN2B 105/4885DRD2 38/4885 |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | DRD4 618/4885GRIN2B 332/4885DRD2 341/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | DRD4 32/4885GRIN2B 1107/4885DRD2 27/4885 |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | DRD4 618/4885GRIN2B 332/4885DRD2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.